full free access: Ovarian cancer: relevant therapy, not timing, is paramount : The Lancet

Note: registration required to view (free)

Mayo Clinic - Mayo Clinic Finds Inflammation Causes Some Postsurgical Neuropathies (nerve damage)

The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer

Abstract Aim:  The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer.  

Medscape: No Benefit for Early Tx of Ovarian Cancer Relapse

Note: article discusses the concerns/issues/study etc

Genomics|Update - Breast and Ovarian Cancer Awareness in September and October

media item: New Clues to Treating Ovarian Cancer Relapse

New Clues to Treating Ovarian Cancer Relapse
Starting chemotherapy when first signs reappear not especially effective, study finds "This paper, the first randomized trial to look at the timing of chemo in women with recurring ovarian cancer, appears in the Oct. 2 issue of The Lancet, a special themed issue on cancer...."

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61268-8/abstract
SOURCES: Andrew Berchuck, M.D., director, division of gynecologic oncology, Duke University Medical Center, Durham, N.C.; Robert A. Burger, M.D., professor of surgical oncology, section of gynecologic oncology and director, Women's Cancer Center, Fox Chase Cancer Center, Philadelphia; Oct. 2, 2010, The Lancet